<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Amgen Inc. — News on 6ix</title>
<link>https://6ix.com/company/amgen-inc</link>
<description>Latest news and press releases for Amgen Inc. on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 04 May 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/amgen-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683545d878dffbe2df0e2ba4.webp</url>
<title>Amgen Inc.</title>
<link>https://6ix.com/company/amgen-inc</link>
</image>
<item>
<title>AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEAR</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-announces-additional-dollar300-million-us-manufacturing-investment-totaling-nearly-dollar2-billion-over-the-last-year</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-announces-additional-dollar300-million-us-manufacturing-investment-totaling-nearly-dollar2-billion-over-the-last-year</guid>
<pubDate>Mon, 04 May 2026 13:00:00 GMT</pubDate>
<description>Amgen (NASDAQ: AMGN) today announced plans to invest an additional $300 million in its U.S. manufacturing network to further advance U.S.-based production capacity, enhance next-generation technologies and support a reliable supply of medicines for patients.</description>
</item>
<item>
<title>Blincyto (blinatumomab: Amgen) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F</title>
<link>https://6ix.com/company/amgen-inc/news/blincyto-blinatumomab-amgen-market-research-report-2026-epidemiology-pipeline-analysis-market-insights-and-forecasts-2020-2025-2025-2030f-2035f</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/blincyto-blinatumomab-amgen-market-research-report-2026-epidemiology-pipeline-analysis-market-insights-and-forecasts-2020-2025-2025-2030f-2035f</guid>
<pubDate>Fri, 01 May 2026 12:01:00 GMT</pubDate>
<description>The Blincyto market is poised for growth due to unmet needs in leukemia treatment, advancements in monoclonal antibodies, rising leukemia incidence, and healthcare spending. Key opportunities include precision medicine, immuno-oncology adoption, and regional biologics production, especially in Asia-Pacific and Latin America. Blincyto Market Blincyto Market Dublin, May 01, 2026 (GLOBE NEWSWIRE) -- The "Blincyto Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" has</description>
</item>
<item>
<title>AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-reports-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-reports-first-quarter-2026-financial-results</guid>
<pubDate>Thu, 30 Apr 2026 20:01:00 GMT</pubDate>
<description>Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2026.</description>
</item>
<item>
<title>TOMI Environmental Solutions, Inc. Sees Strong Interest In Its Solutions at INTERPHEX 2026</title>
<link>https://6ix.com/company/amgen-inc/news/tomi-environmental-solutions-inc-sees-strong-interest-in-its-solutions-at-interphex-2026</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/tomi-environmental-solutions-inc-sees-strong-interest-in-its-solutions-at-interphex-2026</guid>
<pubDate>Mon, 27 Apr 2026 12:30:00 GMT</pubDate>
<description>Company Showcases SteraMist iHP Automation to Industry Giants Including Amgen, Merck, and Moderna; Finalizes Custom Engineering Contract for Proprietary Healthcare SystemFREDERICK, Md., April 27, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, saw strong interest in its solutions at “INTERPHEX 2026” reflecting broader market awareness and acceptance of its products and positioning the Company to</description>
</item>
<item>
<title>AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-announces-webcast-of-2026-first-quarter-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-announces-webcast-of-2026-first-quarter-financial-results</guid>
<pubDate>Fri, 24 Apr 2026 20:01:00 GMT</pubDate>
<description>Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.</description>
</item>
<item>
<title>AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-announces-retirement-of-david-m-reese-executive-vice-president-and-chief-technology-officer</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-announces-retirement-of-david-m-reese-executive-vice-president-and-chief-technology-officer</guid>
<pubDate>Wed, 22 Apr 2026 20:00:00 GMT</pubDate>
<description>Amgen (NASDAQ:AMGN) today announced the retirement of David M. Reese, M.D., executive vice president and Chief Technology Officer, effective June 30, 2026.</description>
</item>
<item>
<title>AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-announces-positive-topline-phase-3-results-for-subcutaneous-tepezzar-in-adults-living-with-moderate-to-severe-active-thyroid-eye-disease</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-announces-positive-topline-phase-3-results-for-subcutaneous-tepezzar-in-adults-living-with-moderate-to-severe-active-thyroid-eye-disease</guid>
<pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
<description>Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful</description>
</item>
<item>
<title>Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy</title>
<link>https://6ix.com/company/amgen-inc/news/zai-lab-announces-global-clinical-trial-collaboration-and-supply-agreement-to-evaluate-novel-dll3-adc-zocilurtatug-pelitecan-in-combination-with-a-bispecific-t-cell-engager-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/zai-lab-announces-global-clinical-trial-collaboration-and-supply-agreement-to-evaluate-novel-dll3-adc-zocilurtatug-pelitecan-in-combination-with-a-bispecific-t-cell-engager-therapy</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>- Collaboration with Amgen to explore the clinical potential of Zai Lab’s DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen’s IMDELLTRA®</description>
</item>
<item>
<title>REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS</title>
<link>https://6ix.com/company/amgen-inc/news/repathar-cuts-risk-of-first-major-cardiovascular-events-by-31percent-in-high-risk-patients-without-known-significant-atherosclerosis</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/repathar-cuts-risk-of-first-major-cardiovascular-events-by-31percent-in-high-risk-patients-without-known-significant-atherosclerosis</guid>
<pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
<description>Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary PreventionVESALIUS-CV Subgroup Findings Reinforce</description>
</item>
<item>
<title>Rapid Micro Biosystems Reports Record Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Guidance</title>
<link>https://6ix.com/company/amgen-inc/news/rapid-micro-biosystems-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-guidance-6</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/rapid-micro-biosystems-reports-record-fourth-quarter-and-full-year-2025-financial-results-and-provides-2026-guidance-6</guid>
<pubDate>Thu, 12 Mar 2026 11:00:00 GMT</pubDate>
<description>Reports record fourth quarter 2025 total revenue of $11.3 million, representing 37% growth compared to fourth quarter 2024Reports full year 2025 total revenue of $33.6 million, representing 20% growth compared to 2024Amgen expands global Growth Direct system rollout with significant multi-system order in the fourth quarter 2025; will sponsor North American Growth Direct Day in the second quarter 2026Samsung Biologics continues to expand Growth Direct deployment across its manufacturing network w</description>
</item>
<item>
<title>AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-to-present-at-the-leerink-partners-2026-global-healthcare-conference-29</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-to-present-at-the-leerink-partners-2026-global-healthcare-conference-29</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., March 5, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference at 9:20 a.m.</description>
</item>
<item>
<title>AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-announces-2026-second-quarter-dividend-46</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-announces-2026-second-quarter-dividend-46</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for</description>
</item>
<item>
<title>Absci Strengthens Clinical Leadership with Appointment of Ransi Somaratne, M.D., FACC, MBA as Chief Medical Officer</title>
<link>https://6ix.com/company/amgen-inc/news/absci-strengthens-clinical-leadership-with-appointment-of-ransi-somaratne-md-facc-mba-as-chief-medical-officer-2</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/absci-strengthens-clinical-leadership-with-appointment-of-ransi-somaratne-md-facc-mba-as-chief-medical-officer-2</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>Former Vertex executive to spearhead the clinical development of Absci’s expanding AI-designed therapeutics pipeline Chief Innovation Officer Andreas Busch to retire March 31, 2026 and will continue to co-chair Absci’s Scientific Advisory Board VANCOUVER, Wash. and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics designed with generative AI, today announced the appointment of Ransi Somara</description>
</item>
<item>
<title>AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-to-present-at-the-46th-annual-td-cowen-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-to-present-at-the-46th-annual-td-cowen-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 21:01:00 GMT</pubDate>
<description>Amgen (NASDAQ:AMGN) will present at the 46th Annual TD Cowen Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026. Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, and Justin Claeys, senior vice president of Finance at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.</description>
</item>
<item>
<title>MATTERWORKS, INC. ANNOUNCES UPDATE TO LEADERSHIP TEAM</title>
<link>https://6ix.com/company/amgen-inc/news/matterworks-inc-announces-update-to-leadership-team</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/matterworks-inc-announces-update-to-leadership-team</guid>
<pubDate>Tue, 17 Feb 2026 16:30:00 GMT</pubDate>
<description>Matterworks, Inc., a frontier AI company providing predictive biology tools that accelerate discovery, development and manufacturing across life science applications, announced that Paul Stone has joined the company as Chief Financial Officer and Head of Corporate Development. Mr. Stone is a life sciences executive with over twenty-eight years of experience and leadership roles in venture capital and operating companies. He joins Matterworks from 5AM Ventures (Partner), following his most recent</description>
</item>
<item>
<title>AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-present-citis-2026-virtual-210100489</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-present-citis-2026-virtual-210100489</guid>
<pubDate>Fri, 13 Feb 2026 21:01:00 GMT</pubDate>
<description>Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit at 12:15 p.m. PT on Wednesday, Feb. 18, 2026. Jean-Charles Soria, senior vice president of oncology within global development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.</description>
</item>
<item>
<title>BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration</title>
<link>https://6ix.com/company/amgen-inc/news/biophorum-announces-formation-of-strategic-advisory-board-to-accelerate-industry-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/biophorum-announces-formation-of-strategic-advisory-board-to-accelerate-industry-collaboration</guid>
<pubDate>Thu, 05 Feb 2026 09:00:00 GMT</pubDate>
<description>BioPhorum, the pharmaceutical industry's most trusted collaborative network for change, today announces the formation of its inaugural Strategic Advisory Board.</description>
</item>
<item>
<title>AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-reports-fourth-quarter-full-210100986</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-reports-fourth-quarter-full-210100986</guid>
<pubDate>Tue, 03 Feb 2026 21:01:00 GMT</pubDate>
<description>Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024.</description>
</item>
<item>
<title>AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-announces-webcast-2025-fourth-210100316</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-announces-webcast-2025-fourth-210100316</guid>
<pubDate>Wed, 28 Jan 2026 21:01:00 GMT</pubDate>
<description>Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.</description>
</item>
<item>
<title>Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference</title>
<link>https://6ix.com/company/amgen-inc/news/biocom-announces-powerhouse-keynote-panel-featuring-heads-of-discovery-and-research-and-development-from-abbvie-amgen-and-eli-lilly-at-2026-global-partnering-and-investor-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/biocom-announces-powerhouse-keynote-panel-featuring-heads-of-discovery-and-research-and-development-from-abbvie-amgen-and-eli-lilly-at-2026-global-partnering-and-investor-conference-1</guid>
<pubDate>Wed, 21 Jan 2026 14:02:00 GMT</pubDate>
<description>SAN DIEGO, January 21, 2026--Biocom today announced a distinguished keynote session for its 2026 Global Partnering & Investor Conference, taking place February 24 to 26 at The Lodge at Torrey Pines in La Jolla, California.</description>
</item>
</channel>
</rss>